Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!

Range Low Price High Price Comment
30 days $0.250 $0.685 Friday, 10th May 2024 ADXS stock ended at $0.437. This is 21.96% less than the trading day before Thursday, 9th May 2024. During the day the stock fluctuated 108.00% from a day low at $0.250 to a day high of $0.520.
90 days $0.250 $1.05
52 weeks $0.250 $1.95

Historical Advaxis prices

Date Open High Low Close Volume
Jan 04, 2017 $113.70 $119.25 $111.75 $119.10 45 678
Jan 03, 2017 $108.75 $112.95 $108.00 $112.35 39 913
Dec 30, 2016 $106.95 $109.20 $104.55 $107.40 52 984
Dec 29, 2016 $108.75 $109.35 $105.00 $106.95 52 030
Dec 28, 2016 $112.80 $115.20 $107.70 $108.90 28 520
Dec 27, 2016 $115.50 $120.00 $111.15 $113.10 46 301
Dec 23, 2016 $107.70 $114.90 $107.70 $114.30 46 287
Dec 22, 2016 $117.60 $118.35 $106.05 $108.15 80 041
Dec 21, 2016 $120.60 $123.75 $117.00 $117.90 64 360
Dec 20, 2016 $120.90 $125.10 $120.00 $120.60 33 992
Dec 19, 2016 $122.70 $125.40 $119.40 $120.30 39 390
Dec 16, 2016 $120.00 $124.65 $120.00 $122.40 46 078
Dec 15, 2016 $123.30 $124.20 $119.25 $121.80 70 126
Dec 14, 2016 $128.40 $131.25 $120.30 $121.80 48 705
Dec 13, 2016 $132.90 $133.50 $127.05 $128.25 26 034
Dec 12, 2016 $132.45 $135.15 $129.60 $132.15 31 710
Dec 09, 2016 $133.80 $139.05 $131.40 $133.80 37 870
Dec 08, 2016 $129.00 $132.60 $126.45 $132.45 23 020
Dec 07, 2016 $131.70 $132.75 $126.00 $129.15 41 156
Dec 06, 2016 $129.00 $133.95 $124.50 $133.65 38 209
Dec 05, 2016 $124.80 $129.75 $123.75 $129.30 41 982
Dec 02, 2016 $119.55 $126.30 $117.15 $123.75 28 125
Dec 01, 2016 $124.95 $125.85 $119.25 $120.30 56 716
Nov 30, 2016 $135.00 $136.35 $124.65 $124.65 49 496
Nov 29, 2016 $132.45 $133.65 $126.30 $128.40 54 994
Click to get the best stock tips daily for free!

About Advaxis

Advaxis Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for... ADXS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT